Literature DB >> 21772589

Pasi and pqol-12 score in psoriasis: is there any correlation?

Vikas Shankar1, Sanjay Ghosh, Kisalay Ghosh, Uday Chaudhuri.   

Abstract

BACKGROUND: Psoriasis, a common papulo-squamous disorder of the skin, is universal in occurrence and may interfere with the quality of life adversely. Whether extent of the disease has any bearing upon the patients' psychology has not much been studied in this part of the world. AIMS: The objective of this hospital-based cross-sectional study was to assess the disease severity objectively using Psoriasis area and severity index (PASI) score and the quality of life by Psoriasis quality-of-life questionnaire-12 (PQOL-12) and to draw correlation between them, if any.
MATERIALS AND METHODS: PASI score denotes an objective method of scoring severity of psoriasis, reflecting not only the body surface area but also erythema, induration and scaling. The PQOL-12 represents a 12-item self-administered, disease-specific psychometric instrument created to specifically assess quality-of-life issues that are more important with psoriasis patients.PASI and PQOL-12 score were calculated in each patient for objectively assessing their disease severity and quality of life.
RESULTS: In total, 34 psoriasis patients (16 males, 18 females), of age ranging from 8 to 55 years, were studied. Maximum and minimum PASI scores were 0.8 and 32.8, respectively, whereas maximum and minimum PQOL-12 scores were 4 and 120, respectively. PASI and PQOL-12 values showed minimal positive correlation (r = +0.422).
CONCLUSION: Disease severity of psoriasis had no direct reflection upon their quality of life. Limited psoriasis on visible area may also have greater impact on mental health.

Entities:  

Keywords:  PASI; Psoriasis; Psoriasis area and severity index; Psoriasis quality-of-life questionnaire-12; quality of life

Year:  2011        PMID: 21772589      PMCID: PMC3132905          DOI: 10.4103/0019-5154.82482

Source DB:  PubMed          Journal:  Indian J Dermatol        ISSN: 0019-5154            Impact factor:   1.494


Introduction

Psoriasis, a common and chronic papulo-squamous disorder of the skin, is universal in occurrence. Like other chronic dermatoses, patients’ daily functioning and quality of life can be disturbed by psoriasis.[12] Degree of the disease severity may have some reflection on the quality of life. Very few Indian studies[34] have enlightened us on this aspect of psoriasis. The chief object of the present study was to assess objectively the extent of the disease and the quality of life and to draw correlation between them, if any.

Materials and Methods

Place and time

The study was conducted in the Department of Dermatology, MGM Medical College and LSK Hospital, Kishanganj, Bihar, India, from November 2008 to August 2009. This was a hospital-based cross-sectional study.

Inclusion and exclusion criteria

Inclusion criteria for the patients were all morphological variants of psoriasis with or without joint involvement, pre-treated or untreated. In case of any dilemma in clinical diagnosis, confirmation was done by histopathological test. Exclusion criteria were: (1) psoriasiform dermatoses due to other etiologies like drugs, etc., (2) psoriatic arthropathy without skin involvement, (3) nail psoriasis without skin involvement, (4) generalized pustular psoriasis de novo without any associated or previous history of psoriatic plaque (5) sebo-psoriasis, palmo-plantar pustulosis or inverse psoriasis presenting alone morphologically without any other classical clinical presentation of psoriasis elsewhere in the skin.

Clinical evaluation

Detailed record of demographic and clinical features was noted in “Case Record Proforma”. Family history was traced in detail. Digital photographs of all the patients were taken and preserved. Microphotographs of the histopathological features were kept when skin biopsy was performed.

Psoriasis areas and severity index score

Psoriasis areas and severity index (PASI) score denotes an objective method of scoring severity of psoriasis, reflecting not only the body surface area but also erythema, induration and scaling.[5] PASI score was measured and recorded in each patient.

Psoriasis quality-of-life questionniare-12 score

Psoriasis Quality-of-life Questionniare-12 (PQOL-12) represents a 12-item self-administered, disease-specific psychometric instrument [Figure 1] created to specifically assess quality-of-life issues that are more important with psoriasis patients.[6] PQOL-12 was detected in each patient for objectively assessing their quality of life.
Figure 1

The PQOL-12 score: Koo-Mentor Psoriasis Instrument[6]

The PQOL-12 score: Koo-Mentor Psoriasis Instrument[6]

Results

In total, 34 (16 males, 18 females) patients were enrolled in the study. Their age ranged from 8 to 55 years, median being 33.5 years. Duration of disease was from 1 month to 20 years. Maximum and minimum PASI scores were 0.8 and 32.8, respectively, whereas maximum and minimum PQOL-12 scores were 4 and 120, respectively [Table 1].
Table 1

Age, sex, duration, site with PQOL-12 and PASI in patients

Age, sex, duration, site with PQOL-12 and PASI in patients PASI and PQOL-12 values showed [Figure 2] only partial positive correlation (r = +0.422) among themselves.
Figure 2

Correlation graph between PASI and PQOL-12 value ; XY (scatter) graph showing minimal positive correlation

Correlation graph between PASI and PQOL-12 value ; XY (scatter) graph showing minimal positive correlation

Discussion

Several studies from abroad have explored the association between clinical severity of psoriasis and quality of life. Finlay,[7] Aschrof,[8] and Gelfand[9] have demonstrated moderate correlation between the extent of the disease and physical disability. A South Indian study[3] has depicted similar finding of positive correlation between PASI and psoriasis disability index (PDI) scores. A study from northern India[4] has also shown that psychiatric morbidity significantly correlated with dysfunction induced by psoriasis. However, Fortune,[10] Heydendael,[11] and Yang[12] could not find any significant correlation between PASI score and quality of life. Our study also could not show any significant correlation between the extent of the disease and PQOL-12 score. Severe psoriasis is manifested in different facets, including erythema, infiltration, and desquamation. Fallacy of the PASI score measurement lies in the fact[11] that several quite different patterns of psoriasis can yield similar PASI. Moreover, quality of life may be influenced by a large number of factors including age and co-morbidity. Psoriatic lesions located on visible parts of the body also had a significant impact on the quality of life, especially mental health.[11] Lesions on legs, arms and head had a more profound impact on the quality of life than lesions located on other parts of the body.[12] Cosmetic disfigurement and itching may also determine the burden of the disease,[11] which were not taken into account in the previous disease-specific psychometric instrument created to specifically assess quality-of-life of psoriasis. However, the instrument used in the present study like PQOL-12 has envisaged these two parameters as well. Our study concludes that disease severity of psoriasis has minimal correlation with quality of life. Even limited psoriasis, especially located on visible parts of the body, may induce great psychological trauma to the patients.
  9 in total

1.  Validation of Sickness Impact Profile and Psoriasis Disability Index in Psoriasis.

Authors:  A Y Finlay; G K Khan; D K Luscombe; M S Salek
Journal:  Br J Dermatol       Date:  1990-12       Impact factor: 9.302

Review 2.  Quality of life measures in psoriasis: a critical appraisal of their quality.

Authors:  D M Ashcroft; A Li Wan Po; H C Williams; C E Griffiths
Journal:  J Clin Pharm Ther       Date:  1998-10       Impact factor: 2.512

3.  Postal questionnaire study of disability in the community associated with psoriasis.

Authors:  P O'Neill; P Kelly
Journal:  BMJ       Date:  1996-10-12

4.  The psoriasis disability index in Chinese patients: contribution of clinical and psychological variables.

Authors:  Yong Yang; David Koh; Lawrence Khoo; Shwe Zin Nyunt; Vivian Ng; Chee Leok Goh
Journal:  Int J Dermatol       Date:  2005-11       Impact factor: 2.736

5.  Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress.

Authors:  D G Fortune; C J Main; T M O'Sullivan; C E Griffiths
Journal:  Br J Dermatol       Date:  1997-11       Impact factor: 9.302

6.  Determinants of quality of life in patients with psoriasis: a study from the US population.

Authors:  Joel M Gelfand; Steven R Feldman; Robert S Stern; John Thomas; Tara Rolstad; David J Margolis
Journal:  J Am Acad Dermatol       Date:  2004-11       Impact factor: 11.527

7.  Quality of life in psoriasis: a study from south India.

Authors:  S V Rakhesh; Mariette D'Souza; Ajith Sahai
Journal:  Indian J Dermatol Venereol Leprol       Date:  2008 Nov-Dec       Impact factor: 2.545

8.  The burden of psoriasis is not determined by disease severity only.

Authors:  Vera M Heydendael; Corianne A de Borgie; Phyllis I Spuls; Patrick M Bossuyt; Jan D Bos; Menno A de Rie
Journal:  J Investig Dermatol Symp Proc       Date:  2004-03

9.  The effect of severe psoriasis on the quality of life of 369 patients.

Authors:  A Y Finlay; E C Coles
Journal:  Br J Dermatol       Date:  1995-02       Impact factor: 9.302

  9 in total
  6 in total

1.  Evaluation of some psychological factors in psoriatic patients.

Authors:  Pedram Noormohammadpour; Yousef Fakour; Mohammad Javad Nazemei; Amirhooshang Ehsani; Fatemeh Gholamali; Afsaneh Morteza; Leila Mokhtari; Najmeh Khosrovanmehr
Journal:  Iran J Psychiatry       Date:  2015

2.  General measures and quality of life issues in psoriasis.

Authors:  Rashmi Sarkar; Shikha Chugh; Shivani Bansal
Journal:  Indian Dermatol Online J       Date:  2016 Nov-Dec

3.  A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life.

Authors:  V V Karamata; A M Gandhi; P P Patel; A Sutaria; M K Desai
Journal:  Indian J Pharmacol       Date:  2017 Jan-Feb       Impact factor: 1.200

4.  Dermatology Life Quality Index and disease coping strategies in psoriasis patients.

Authors:  Sopiko Liluashvili; Tina Kituashvili
Journal:  Postepy Dermatol Alergol       Date:  2019-08-30       Impact factor: 1.837

5.  The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  Ali Akbarzadeh; Pedram Alirezaei; Amin Doosti-Irani; Maryam Mehrpooya; Fatemeh Nouri
Journal:  Dermatol Res Pract       Date:  2022-10-07

6.  Fixed-dose combination calcipotriol/betamethasone dipropionate foam provides a rapid onset of action, effective itch relief and improves patient quality of life.

Authors:  A Jalili; G Yosipovitch
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-02       Impact factor: 6.166

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.